Usefulness of Faecal Calprotectin Measurement in Children with Various Types of Inflammatory Bowel Disease

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2012 Jun 6

PMID 22665952

Citations 12

Authors

Marzena Komraus

Halina Wos

Sabina Wiecek

Maciej Kajor

Urszula Grzybowska-Chlebowczyk

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of the study was to assess the usefulness of the FC measurement in children with various types of IBD and relation to the disease activity.

Patients And Methods: 91 patients (49 boys: 53.85% and 42 girls: 46.15%, mean age: 13.38 years, range 6-18 years) were included in the analysis. Patients were divided into the groups: B1-24 children with CD, B2-16 patients with UC, and a group comprising 31 children with other types of colitis; the control group (K) comprised 20 healthy children. FC was assayed by ELISA method, using Phical test (Calpro).

Results: The mean faecal calprotectin concentrations were higher in children with CD and UC as compared to healthy controls, patients with eosinophilic, lymphocytic, and nonspecific colitis. A positive correlation was observed between FC concentrations and the disease activity (the PCDAI scale, the Truelove-Witts Scale, and the endoscopic Rachmilewitz Index).

Conclusion: It seems that the FC concentrations can be a useful, safe, and noninvasive test in children suspected for IBD, since FC concentration is higher in children with CD and UC than in patients with other inflammatory diseases.

Citing Articles

Assessing the correlation between fecal calprotectin, blood markers and disease activity in pediatric inflammatory bowel disease.

Plume J, De A, Mutalib M Ann Gastroenterol. 2024; 37(4):436-441.

PMID: 38974077 PMC: 11226738. DOI: 10.20524/aog.2024.0892.

Evaluation of Fecal Calprotectin, Serum C-Reactive Protein, Erythrocyte Sedimentation Rate, Seromucoid and Procalcitonin in the Diagnostics and Monitoring of Crohn's Disease in Children.

Akutko K, Iwanczak B J Clin Med. 2022; 11(20).

PMID: 36294408 PMC: 9604851. DOI: 10.3390/jcm11206086.

Association of fecal calprotectin level with eosinophilic gastrointestinal disease in Iranian pediatrics.

Rohani P, Beheshti N, Alimadadi H, Sohouli M Allergy Asthma Clin Immunol. 2022; 18(1):86.

PMID: 36180889 PMC: 9526333. DOI: 10.1186/s13223-022-00728-5.

Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn's disease?: a systematic review.

Simon E, Wardle R, Thi A, Eldridge J, Samuel S, Moran G Intest Res. 2019; 17(2):160-170.

PMID: 30704158 PMC: 6505091. DOI: 10.5217/ir.2018.00114.

The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis.

Wiecek S, Wos H, Kordys-Darmolinska B, Sankiewicz-Szkolka M, Grzybowska-Chlebowczyk U Prz Gastroenterol. 2017; 12(1):38-43.

PMID: 28337235 PMC: 5360654. DOI: 10.5114/pg.2016.58897.

References

Fagerberg U, Loof L, Lindholm J, Hansson L, Finkel Y . Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 45(4):414-20. DOI: 10.1097/MPG.0b013e31810e75a9. View

Roseth A, Aadland E, Jahnsen J, Raknerud N . Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997; 58(2):176-80. DOI: 10.1159/000201441. View

Roseth A, Aadland E, Grzyb K . Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004; 39(10):1017-20. DOI: 10.1080/00365520410007971. View

Bremner A, Roked S, Robinson R, Phillips I, Beattie M . Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 2006; 94(12):1855-8. DOI: 10.1111/j.1651-2227.2005.tb01870.x. View

Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F . Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem. 2003; 49(6 Pt 1):861-7. DOI: 10.1373/49.6.861. View

Konikoff M, Denson L . Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12(6):524-34. DOI: 10.1097/00054725-200606000-00013. View

Grzybowska-Chlebowczyk U, Wos H, Sieron A, Kajor M, Wiecek S, Koryciak-Komarska H . [Parenteral symptoms and intestinal complications in children with inflammatory bowel diseases in relation to card15 mutation]. Med Wieku Rozwoj. 2009; 12(3):754-60. View

Fagerberg U, Loof L, Myrdal U, Hansson L, Finkel Y . Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005; 40(4):450-5. DOI: 10.1097/01.mpg.0000154657.08994.94. View

Joishy M, Davies I, Ahmed M, Wassel J, Davies K, Sayers A . Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009; 48(1):48-54. DOI: 10.1097/MPG.0b013e31816533d3. View

10.

Leach S, Day A . S100 proteins in the pathogenesis and diagnosis of inflammatory bowel disease. Expert Rev Clin Immunol. 2010; 2(3):471-80. DOI: 10.1586/1744666X.2.3.471. View

11.

Costa F, Mumolo M, Ceccarelli L, Bellini M, Romano M, Sterpi C . Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54(3):364-8. PMC: 1774401. DOI: 10.1136/gut.2004.043406. View

12.

Helio T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U . CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut. 2003; 52(4):558-62. PMC: 1773614. DOI: 10.1136/gut.52.4.558. View

13.

Berni Canani R, de Horatio L, Terrin G, Romano M, Miele E, Staiano A . Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2005; 42(1):9-15. DOI: 10.1097/01.mpg.0000187818.76954.9a. View

14.

Bunn S, Bisset W, Main M, Gray E, Olson S, Golden B . Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001; 33(1):14-22. DOI: 10.1097/00005176-200107000-00003. View

15.

Geboes K, De Hertogh G . Indeterminate colitis. Inflamm Bowel Dis. 2003; 9(5):324-31. DOI: 10.1097/00054725-200309000-00007. View

16.

Tibble J, Bjarnason I . Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2002; 7(4):460-5. PMC: 4688655. DOI: 10.3748/wjg.v7.i4.460. View